| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We conducted a multicenter cross-sectional study to assess mumps breakthrough infection. Students from three universities participated in 2019. Informed consent was obtained from the students and their guardians. We collected data on past history and vaccination history using a questionnaire, photocopies of the Maternal and Child Health Handbook, and virus antibody titers. This study assessed 2004 students and included 593 (30%); of these, 250 (43%) had a mumps infection history. Furthermore, 264 (45%), 31 (5%), and 2 (0.3%) students received the first, second, and third doses of mumps vaccine. The mumps seropositivity prevalence was 43% (n = 127), 37% (n = 97), 27% (n = 8), and 100% (n = 2) (p for trend = 0.09), and the mumps infection prevalence rates were 70% (n = 203), 11% (n = 28), 4% (n = 1), and 0%, for the no-, first-, second-, and third-dose groups. Approximately 1 in 10 students receiving only one dose of mumps-containing vaccine had a breakthrough infection history.
|
